Case Study: a leading pharma company strengthens oncology pipeline prioritization with C5i

Early asset prioritization in oncology

The leading pharma company, a major player in oncology, required a way to continuously monitor and evaluate the competitive landscape of early-stage assets to strategically strengthen its oncology pipeline. To address this, they engaged C5i for its analytics and intelligence services to gain insights on key mechanisms of action and competitor developments.

C5i implemented a comprehensive secondary research methodology and a dynamic asset prioritization model to score molecules across parameters like clinical data, innovation, and intellectual property. This solution provided the client with prioritized lists of molecules and risk analysis, enabling more effective R&D efforts and strategic decision-making. The work by C5i strengthened the client's oncology franchise by improving the positioning of their pipeline products and facilitating the evaluation of new opportunities.